Welcome to our dedicated page for Stryker SEC filings (Ticker: SYK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stryker Corporation filings document the regulatory record of a New York Stock Exchange-listed medical technology issuer with operations in MedSurg, Neurotechnology and Orthopaedics. Its 8-K reports cover operating results, financial-condition updates, material events, Regulation FD disclosures and exhibits tied to company press releases.
The filing record also describes governance and capital-structure matters, including definitive proxy materials, annual-meeting votes, director elections, auditor ratification, executive-compensation votes, common stock and listed senior unsecured notes. Recent material-event filings include cybersecurity incident disclosures and amendments describing operational and reporting updates connected to Stryker's information technology environment.
Stryker Corporation reports strong 2025 growth as a global medical technology leader. Net sales reached $25.1 billion, up from $22.6 billion in 2024, led by MedSurg and Neurotechnology at $15.6 billion and Orthopaedics at $9.5 billion. Net earnings were $3.25 billion, or $8.40 diluted EPS.
The company completed roughly $5.0 billion of acquisitions, including Inari Medical, expanding its Vascular portfolio for venous thromboembolism treatment. Stryker invested $1.62 billion in research, development and engineering and ended the year with $4.10 billion in cash and equivalents and $15.9 billion of total debt.
Stryker issued new senior notes totaling $3.0 billion and expanded its revolving credit facility to $3.0 billion maturing in 2030. The company paid $1.28 billion in dividends and employed about 56,000 people worldwide as of December 31, 2025.
Stryker Corporation director Ronda E. Stryker, through a revocable trust, reported a series of open-market sales of Stryker common stock on February 4–5, 2026. The revocable trust sold multiple blocks of shares at weighted average prices ranging from $358.005 to $368.635 per share, as detailed in the footnotes. After these transactions, the revocable trust held 2,207,331 Stryker shares, with additional indirect holdings of 13,578,805 shares by the L. Lee Stryker Trust and 37,600 shares by the 1988 William D. Johnston Trust, plus 560 shares held directly.
Stryker Corporation reported an equity award transaction for VP and Chief Accounting Officer William E. Berry Jr. on February 4, 2026. He received a grant of 797 restricted stock units with no cash price per unit, increasing his directly held common stock to 3,602 shares, plus 615 shares held indirectly through a 401(k) plan.
Each RSU represents a contingent right to receive one share of Stryker common stock and is scheduled to vest in three equal installments on March 21, 2027, March 21, 2028, and March 21, 2029. Berry also received an employee stock option for 2,391 shares at an exercise price of $360.82, which becomes exercisable as to 20% of the option on each of the first five anniversaries of the grant date and expires on February 3, 2036.
Stryker Corporation reported that VP and Chief Commercial Officer Kimberly Ann Montagnino received an employee stock option grant on February 4, 2026. The option covers 1,830 shares of Stryker common stock at an exercise price of $360.82 per share.
The grant was issued under the Stryker Corporation 2011 Long-Term Incentive Plan and is exercisable as to 20% of the option on each of the first five anniversaries of the grant date. Following this award, she directly holds options for 1,830 shares.
Stryker Corporation reported that officer Debra King received a new stock option award. On February 4, 2026, she was granted 3,992 employee stock options with an exercise price of $360.82 per share under the Stryker Corporation 2011 Long-Term Incentive Plan.
The options vest in stages, becoming exercisable as to 20% on each of the first five anniversaries of the grant date, and are scheduled to expire on February 3, 2036. After this grant, King beneficially owns 3,992 derivative securities directly as VP, Chief Digital and Information Officer.
Stryker Corporation reported that VP and Chief HR Officer M. Kathryn Fink received an employee stock option award. On 02/04/2026 she was granted options to purchase 5,654 shares of Stryker common stock at an exercise price of $360.82 per share.
These options vest in stages, with 20% becoming exercisable on each of the first five anniversaries of the grant date, and they expire on 02/03/2036. The grant was made under the Stryker Corporation 2011 Long-Term Incentive Plan and is held directly by the executive.
Stryker Corporation granted a new stock option award to its VP and Chief Legal Officer, Robert S. Fletcher. On 02/04/2026, he received an employee stock option for 8,980 shares of Stryker common stock at an exercise price of $360.82 per share.
The option was granted under the Stryker Corporation 2011 Long-Term Incentive Plan and becomes exercisable as to 20% on each of the first five anniversaries of the grant date, creating a five-year vesting schedule tied to continued service.
Stryker Corporation granted stock options to senior executive Dylan Bram Crotty, its Group President. On 02/04/2026, he received an employee stock option for 9,978 shares of common stock at an exercise price of $360.82 per share, held directly.
The option was granted under the Stryker Corporation 2011 Long-Term Incentive Plan and becomes exercisable as to 20% of the shares on each of the first five anniversaries of the grant date, with an expiration date of 02/03/2036.
Stryker Corporation reported that Group President Viju Menon received an employee stock option grant on February 4, 2026. The award covers 10,310 options to buy Stryker common stock at an exercise price of $360.82 per share.
These options were granted under the Stryker Corporation 2011 Long-Term Incentive Plan and become exercisable in stages, with 20% vesting on each of the first five anniversaries of the grant date. Following this grant, Menon beneficially owns 10,310 derivative securities directly in the form of these options.
Stryker Corporation reported that its VP and Chief Financial Officer, Preston Wendell Wells, received an employee stock option grant. On February 4, 2026, he was granted 11,974 stock options with an exercise price of $360.82 per share under the Stryker Corporation 2011 Long-Term Incentive Plan.
The options vest in stages, becoming exercisable as to 20% on each of the first five anniversaries of the grant date, and are scheduled to expire on February 3, 2036. Following this grant, he beneficially owns 11,974 derivative securities directly.